Total number of patients, n (%) |
29 (2020. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R: Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer. 1995; 31A: 1599-604.) |
44 (3030. Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, et al.: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987; 2: 294-8.) |
27 (1818. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al.: EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011; 60: 304-19.) |
47 (32) |
0.037
|
Mean patients' age, years ± SD |
27.6 ± 8.4 |
30.2 ± 8.8 |
31.7 ± 8.5 |
32.4 ± 8.5 |
0.089
|
|
|
|
|
|
(11. Meeks JJ, Sheinfeld J, Eggener SE: Environmental toxicology of testicular cancer. Urol Oncol. 2012; 30: 212-5.) vs (33. Steele GS, Richie JP, Stewart AK, Menck HR: The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer. 1999; 86: 2171-83.): 0.065 (11. Meeks JJ, Sheinfeld J, Eggener SE: Environmental toxicology of testicular cancer. Urol Oncol. 2012; 30: 212-5.) vs (44. WHO: International histological classification of tumours. 2nd ed. Geneva: WHO; 1981-1999.): 0.015
|
Histological condition, n (%)
|
|
|
|
|
|
Seminomatous elements |
12 (43) |
15 (36) |
8 (35) |
17 (40) |
0.926 |
Embryonal carcinoma elements |
18 (86) |
29 (88) |
19 (73) |
33 (70) |
0.204 |
Yolk sac elements |
2 (1010. Cooper DE, L'esperance JO, Christman MS, Auge BK: Testis cancer: a 20-year epidemiological review of the experience at a regional military medical facility. J Urol. 2008; 180: 577-81; discussion 581-2.) |
3 (99. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE: Trends in the incidence of testicular germ cell tumors in the United States. Cancer. 2003; 97: 63-70.) |
10 (39) |
15 (32) |
0.011
|
Teratomatous elements |
10 (48) |
18 (55) |
15 (58) |
28 (60) |
0.827 |
Choriocarcinoma elements |
3 (1414. Kratzik C, Höltl W, Albrecht W, Pont J, Zielinski CH, Breindl E, et al.: Risk adapted management for NSGCT stage 1 - longterm results of a multicenter study. J Urol. 1996; 157: 547A.) |
6 (1818. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al.: EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011; 60: 304-19.) |
3 (1212. Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T: The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int. 2005; 95: 1197-200.) |
8 (1717. Molina Saera J, Aparicio Urtasun J, Díaz Beveridge R, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, et al.: Epidemiological pattern and time trends in testicular germ-cell tumors: a single institution 20-year experience. Clin Transl Oncol. 2006; 8: 588-93.) |
0.901 |
Mean tumor size, cm ± SD |
4.2 ± 2.8 |
3.8 ± 1.8 |
3.0 ± 1.8 |
3.9 ± 2.2 |
0.266 |
|
|
|
|
|
(11. Meeks JJ, Sheinfeld J, Eggener SE: Environmental toxicology of testicular cancer. Urol Oncol. 2012; 30: 212-5.) vs (33. Steele GS, Richie JP, Stewart AK, Menck HR: The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer. 1999; 86: 2171-83.): 0.068 (33. Steele GS, Richie JP, Stewart AK, Menck HR: The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer. 1999; 86: 2171-83.) vs (44. WHO: International histological classification of tumours. 2nd ed. Geneva: WHO; 1981-1999.): 0.090
|
Presence of vascular invasion, n (%)
|
|
|
|
|
|
Yes |
8 (32) |
13 (31) |
8 (31) |
27 (57) |
0.030
|
pT stage, n (%) |
- |
- |
- |
- |
0.119 |
pT1 |
19 (70) |
31 (72) |
16 (62) |
19 (41) |
0.100 |
pT2 |
3 (1111. Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT, Sluiter WJ, Schraffordt Koops H, Sleijfer DT: The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int. 1999; 84: 68-74.) |
6 (1414. Kratzik C, Höltl W, Albrecht W, Pont J, Zielinski CH, Breindl E, et al.: Risk adapted management for NSGCT stage 1 - longterm results of a multicenter study. J Urol. 1996; 157: 547A.) |
9 (35) |
25 (54) |
< 0.001
|
pT3 |
5 (1919. Laguna MP, Pizzocaro G, Klepp O, Algaba F, Kisbenedek L, Leiva O, et al.: EAU guidelines on testicular cancer. Eur Urol. 2001; 40: 102-10.) |
6 (1414. Kratzik C, Höltl W, Albrecht W, Pont J, Zielinski CH, Breindl E, et al.: Risk adapted management for NSGCT stage 1 - longterm results of a multicenter study. J Urol. 1996; 157: 547A.) |
1 (44. WHO: International histological classification of tumours. 2nd ed. Geneva: WHO; 1981-1999.) |
2 (44. WHO: International histological classification of tumours. 2nd ed. Geneva: WHO; 1981-1999.) |
0.183 |
pT4 |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
n.e. |
Clinical stage, n (%)
|
|
|
|
|
|
I |
12 (41) |
25 (57) |
16 (59) |
28 (59) |
0.040
|
II |
12 (41) |
10 (2323. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, et al.: Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer. 2001; 91: 1304-15.) |
10 (37) |
12 (2626. Guney S, Guney N, Sonmez NC, Ergenekon E: Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis. Med Oncol. 2009; 26: 136-42.) |
0.948 |
III |
5 (1717. Molina Saera J, Aparicio Urtasun J, Díaz Beveridge R, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, et al.: Epidemiological pattern and time trends in testicular germ-cell tumors: a single institution 20-year experience. Clin Transl Oncol. 2006; 8: 588-93.) |
9 (2020. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R: Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer. 1995; 31A: 1599-604.) |
1 (44. WHO: International histological classification of tumours. 2nd ed. Geneva: WHO; 1981-1999.) |
7 (1515. Muir KR, Parkes SE, Lawson S, Thomas AK, Cameron AH, Mann JR: Changing incidence and geographical distribution of malignant paediatric germ cell tumours in the West Midlands Health Authority region, 1957-92. Br J Cancer. 1995; 72: 219-23.) |
0.095
|
> I |
17 (59) |
19 (43) |
11 (41) |
19 (40) |
0.456 |
IGCCCG classification |
|
|
|
|
0.292 |
Good |
10 (59) |
13 (68) |
7 (78) |
10 (53) |
- |
Intermediate |
4 (2424. Bertz J, Dahm S, Haberland J, Kraywinkel K, Kurth BM, Wolf U: Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Prävalenzen zwischen 1990 und 2010. Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin. RKI. 2010.) |
3 (1616. Birch JM, Marsden HB, Swindell R: Pre-natal factors in the origin of germ cell tumours of childhood. Carcinogenesis. 1982; 3: 75-80.) |
1 (44) |
6 (32) |
- |
Poor |
3 (1818. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al.: EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011; 60: 304-19.) |
3 (1616. Birch JM, Marsden HB, Swindell R: Pre-natal factors in the origin of germ cell tumours of childhood. Carcinogenesis. 1982; 3: 75-80.) |
1 (44) |
3 (1616. Birch JM, Marsden HB, Swindell R: Pre-natal factors in the origin of germ cell tumours of childhood. Carcinogenesis. 1982; 3: 75-80.) |
- |
Adjuvant treatment n (%)
|
|
|
|
|
|
CS = I
|
|
|
|
|
|
Surveillance |
1 (88. Heinzelbecker J, Katzmarzik M, Weiss C, Trojan L, Michel MS, Haecker A: Changes of stage, predictive factors and adjuvant treatment modalities in seminomatous testicular cancer from 1987 to 2007 and their impact on the status of metastasis, recurrence-free and overall survival: a single-center analysis. Urol Int. 2011; 87: 282-7.) |
4 (1717. Molina Saera J, Aparicio Urtasun J, Díaz Beveridge R, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, et al.: Epidemiological pattern and time trends in testicular germ-cell tumors: a single institution 20-year experience. Clin Transl Oncol. 2006; 8: 588-93.) |
2 (1313. Oliver RT, Leahy M, Ong J: Combined seminoma/non-seminoma should be considered as intermediate grade germ cell cancer (GCC). Eur J Cancer. 1995; 31A: 1392-4.) |
7 (2828. Sokoloff MH, Joyce GF, Wise M, Urologic Diseases in America Project: Testis cancer. J Urol. 2007; 177: 2030-41.) |
0.432 |
Chemotherapy |
4 (33) |
4 (1414. Kratzik C, Höltl W, Albrecht W, Pont J, Zielinski CH, Breindl E, et al.: Risk adapted management for NSGCT stage 1 - longterm results of a multicenter study. J Urol. 1996; 157: 547A.) |
11 (69) |
16 (64) |
0.004
|
RPLND |
10 (83) |
15 (63) |
5 (31) |
3 (1212. Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T: The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int. 2005; 95: 1197-200.) |
< 0.001
|
Radiation therapy |
0 (0) |
1 (44. WHO: International histological classification of tumours. 2nd ed. Geneva: WHO; 1981-1999.) |
0 (0) |
0 (0) |
0.530 |
CS > I
|
|
|
|
|
|
RPLND |
1 (66. Sobin LH: Wittekind UICC TNM Classification of malignant tumours. C. UICC TNM classification of malignant tumours. 6th ed. New York: Wiley & Sons. 2002.) |
0 (0) |
0 (0) |
1 (55. Sobin LH, Wittekind C: UICC TNM Classification of malignant tumours. 5th ed. New York: Wiley & Sons. 1997.) |
n.e. |
Chemotherapy |
5 (31) |
5 (2626. Guney S, Guney N, Sonmez NC, Ergenekon E: Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis. Med Oncol. 2009; 26: 136-42.) |
10 (91) |
15 (79) |
< 0.001
|
RPLND + Chemotherapy |
10 (63) |
13 (68) |
1 (99. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE: Trends in the incidence of testicular germ cell tumors in the United States. Cancer. 2003; 97: 63-70.) |
3 (1616. Birch JM, Marsden HB, Swindell R: Pre-natal factors in the origin of germ cell tumours of childhood. Carcinogenesis. 1982; 3: 75-80.) |
< 0.001
|